News

Managing Melanoma In Situ

With its increasing incidence and being a precursor to invasive melanoma, the treatment of MIS, in particular lentigo maligna, is a topic of increasingly significant interest. The ideal management of MIS is openly debated.


 

Kristen L. Toren, MD, and Eric C. Parlette, MD

Melanoma is a highly aggressive skin cancer with an increasing incidence. Melanoma in situ is an early, non-invasive form in which the tumor is confined to the epidermis. Treatment of melanoma in situ is challenging due to the frequent subclinical microscopic spread and to the presentation on the head and neck in cosmetically sensitive areas with chronic sun damage. Optimizing tumor eradication is imperative to reduce the potential progression into invasive disease and metastasis, all while maintaining cosmesis. Multiple treatment regimens have been implemented for managing difficult melanoma in situ tumors. We provide a thorough review of surgical, and non-surgical, management of melanoma in situ which can pose therapeutic dilemmas due to size, anatomic location, and subclinical spread.

*For a PDF of the full article, click on the link to the left of this introduction.

Recommended Reading

FDA Postpones Ipilumimab Review
MDedge Dermatology
Benefits of BRAF Inhibitor Confirmed in Metastatic Melanoma
MDedge Dermatology
Making a Neurofibromatosis Type 1 Diagnosis: Check the Armpits!
MDedge Dermatology
NIH at Forefront of New Clinical Trials Push, Director Says
MDedge Dermatology
Primary Care Physicians Performing More Skin Cancer Screenings
MDedge Dermatology
Can Bundled Cancer-Care Payments Save a Bundle?
MDedge Dermatology
FDA Committee Considers Gardasil for Anal Cancer Prevention
MDedge Dermatology
FDA Panel Divided on MelaFind Device
MDedge Dermatology
PV-10 Melanoma Drug Trial Enrolls Patients in Compassionate Use Program
MDedge Dermatology
Mohs Paste for Treating Melanoma: A Revival
MDedge Dermatology